New Zealand markets close in 4 hours
  • NZX 50

    11,845.14
    -2.01 (-0.02%)
     
  • NZD/USD

    0.6344
    -0.0004 (-0.06%)
     
  • NZD/EUR

    0.6235
    -0.0000 (-0.01%)
     
  • ALL ORDS

    7,355.70
    -6.20 (-0.08%)
     
  • ASX 200

    7,101.00
    -4.40 (-0.06%)
     
  • OIL

    86.83
    +0.30 (+0.35%)
     
  • GOLD

    1,788.80
    -0.90 (-0.05%)
     
  • NASDAQ

    13,635.21
    -31.99 (-0.23%)
     
  • FTSE

    7,536.06
    +26.91 (+0.36%)
     
  • Dow Jones

    34,152.01
    +239.61 (+0.71%)
     
  • DAX

    13,910.12
    +93.52 (+0.68%)
     
  • Hang Seng

    19,830.52
    -210.38 (-1.05%)
     
  • NIKKEI 225

    29,117.78
    +248.87 (+0.86%)
     
  • NZD/JPY

    85.0350
    -0.1050 (-0.12%)
     

Corbus Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Updates

·8-min read
  • Company focused on gaining regulatory clarity for late-stage lenabasum program and advancing programs targeting the endocannabinoid system and integrins into the clinic

  • Augmenting the pipeline through business development continues to be a priority

  • Cash and investments on hand of $114M provides projected runway into first quarter of 2024

Norwood, MA, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), an immunology company, today provided corporate updates and reported financial results for the second quarter of 2021.

Corporate updates:

  • Lenabasum: The primary endpoint in the DETERMINE Phase 3 study of lenabasum in dermatomyositis was not met, although evidence of activity was seen in multiple endpoints. The next step for this program is to reach agreement with the FDA on the potential path forward in dermatomyositis. The company expects topline data from the National Institutes of Health-sponsored Phase 2 study of lenabasum in systemic lupus erythematosus in Q4 2021.

  • Cannabinoid receptor type 1 (CB1) program: Corbus’ CB1 inverse agonists are in preclinical development for treatment of metabolic diseases. In an animal model of diet-induced obesity, our most advanced candidate (CRB-556) generates weight loss as a monotherapy, and its combination with a GLP-1 agonist resulted in greater weight loss than with the GLP-1 inhibitor alone. Program is on track for IND in 2022.

  • Cannabinoid receptor type 2 (CB2) program: Corbus’ CB2 agonists are in preclinical development for treatment of cancer in combination with existing therapies, such as checkpoint inhibitors. Corbus compounds inhibit tumor cells proliferation in vitro and have activity as monotherapy in animal models of cancer. Key preclinical data are expected in Q3 2021 that will guide the path to an IND.

  • Anti-TGFβ integrin monoclonal antibody (mAb) program:

    • New data demonstrate CRB-601 is highly effective at inhibiting αvβ8-mediated activation of diffusible and non-diffusible TGFβ in vitro,​ has preliminary efficacy in the syngeneic animal model of lung cancer (Lewis lung carcinoma model), and appears to be significantly more effective (75x) in vitro than ADWA-11 (PF-06940434), an anti-αvβ8 mAb being tested in a Phase 1 study sponsored by Pfizer​.

    • CRB-601 is also up to 10x more potent in vitro than its precursor mAb, C6D4.​

    • Pre-IND work has commenced, and the program is on schedule for anticipated IND in late 2022.

  • CRB-602 (anti-α vβ6/8 mAb) for fibrotic diseases and cancer:

    • CRB-602 inhibits both αvβ6 and αvβ8 and is in preclinical development for fibrotic diseases and cancer.

    • Program is on schedule for an anticipated IND in early 2023.

Yuval Cohen, Ph.D., Chief Executive Officer said, “Corbus recently made significant progress on our plan to expand our pipeline by licensing two integrin-targeting mAbs that we believe offer a promising approach to inhibiting TGFβ. We are on track to progress these assets along with our small molecules that activate or inhibit the endocannabinoid system into the clinic next year.”

Dr. Cohen continued, “With our strong financial position of approximately $114M of cash and investments on hand, we have the resources in place to advance our diversified pipeline.”

Financial Results for First Quarter Ended June 30, 2021:

Revenue from awards and licenses was approximately $137,000 for the three months ended June 30, 2021, compared to approximately $286,000 in the comparable period in 2020.

Operating expenses decreased by $21.6 million to approximately $16.8 million for the three months ended June 30, 2021, compared to $38.4 million in the comparable period in the prior year. The decrease was primarily attributable to decreased clinical trial and drug manufacturing costs, and an overall reduction in compensation expense.

The Company reported a net loss of approximately $17.1 million, or a net loss per diluted share of $0.15, for the three months ended June 30, 2021, compared to a net loss of approximately $38.1 million, or a net loss per diluted share of $0.52, for the same period in 2020.

Subsequent to June 30th the Company received a refundable foreign tax credit of approximately $12.2 million. As of August 10, 2021, the company has $114.3 million of cash on hand which is expected to fund operations into the first quarter of 2024, based on the current planned expenditures.

About Corbus

Corbus is committed to connecting innovation to our purpose of improving lives by developing new medicines that target inflammation, fibrosis, metabolism and immuno-oncology, by building upon our underlying expertise in immunology. Corbus’ current pipeline includes small molecules that activate or inhibit the endocannabinoid system and anti-integrin monoclonal antibodies that block activation of TGFβ. Corbus is headquartered in Norwood, Massachusetts. For more information on Corbus, visit corbuspharma.com. Connect with us on Twitter, LinkedIn and Facebook.

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's restructuring, trial results, product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions.

These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential,” "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors, including the potential impact of the recent COVID-19 pandemic and the potential impact of sustained social distancing efforts, on our operations, clinical development plans and timelines, which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Corbus Pharmaceuticals Contact:

Lindsey Smith, Director, Investor Relations and Corporate Communications
Phone: +1 (617) 415-7749
Investors: ir@corbuspharma.com
Media: mediainfo@corbuspharma.com

Corbus Pharmaceuticals Holdings, Inc.
Condensed Consolidated Balance Sheets

June 30, 2021 (Unaudited)

December 31, 2020

ASSETS

Current assets:

Cash and cash equivalents

$

36,080,292

$

85,433,441

Marketable securities

70,371,664

Restricted cash

100,000

350,000

Stock subscriptions receivable

-

960,033

Prepaid expenses and other current assets

2,625,425

3,712,861

Contract asset

2,402,678

1,618,296

Total current assets

111,580,059

92,074,631

Restricted cash

569,900

669,900

Property and equipment, net

3,517,677

4,067,837

Operating lease right of use assets

4,938,889

5,248,525

Other assets

2,614

234,038

Total assets

$

120,609,139

$

102,294,931

LIABILITIES AND STOCKHOLDERS’ EQUITY

Current liabilities:

Notes payable

$

102,693

$

710,158

Accounts payable

1,878,244

7,381,183

Accrued expenses

15,087,681

22,005,432

Derivative liability

599,000

797,000

Operating lease liabilities, current

1,069,181

1,004,063

Total current liabilities

18,736,799

31,897,836

Long-term debt, net of debt discount

18,373,099

18,029,005

Operating lease liabilities, noncurrent

6,540,040

7,093,165

Total liabilities

43,649,938

57,020,006

Stockholders’ equity

Preferred stock, $0.0001 par value; 10,000,000 shares authorized, no shares issued and outstanding at June 30, 2021 and December 31, 2020

Common stock, $0.0001 par value; 300,000,000 shares authorized, 125,083,006 shares issued and outstanding at June 30, 2021 and 150,000,000 shares authorized, and 98,852,696 shares issued and outstanding at December 31, 2020

12,508

9,885

Additional paid-in capital

414,249,029

349,358,378

Accumulated other comprehensive loss

(5,454

)

Accumulated deficit

(337,296,882

)

(304,093,338

)

Total stockholders’ equity

76,959,201

45,274,925

Total liabilities and stockholders’ equity

$

120,609,139

$

102,294,931


Corbus Pharmaceuticals Holdings, Inc.
Condensed Consolidated Statements of Operations
(Unaudited)

For the Three Months Ended

For the Six Months Ended

June 30,

June 30,

2021

2020

2021

2020

Revenue from awards and licenses

$

136,558

$

286,346

$

784,382

$

2,048,405

Operating expenses:

Research and development

11,265,220

30,686,071

21,986,043

54,633,937

General and administrative

5,572,397

7,738,968

10,913,594

15,438,447

Total operating expenses

16,837,617

38,425,039

32,899,637

70,072,384

Operating loss

(16,701,059

)

(38,138,693

)

(32,115,255

)

(68,023,979

)

Other income (expense), net:

Other income (expense), net

(227,609

)

(242,703

)

Interest income (expense), net

(401,170

)

12,649

(1,047,720

)

114,642

Change in fair value of derivative liability

204,000

198,000

Foreign currency exchange gain (loss), net

(12,538

)

20,721

4,134

147,214

Other income (expense), net

(437,317

)

33,370

(1,088,289

)

261,856

Net loss

$

(17,138,376

)

$

(38,105,323

)

$

(33,203,544

)

$

(67,762,123

)

Net loss per share, basic and diluted

$

(0.15

)

$

(0.52

)

$

(0.28

)

$

(0.95

)

Weighted average number of common shares outstanding, basic and diluted

116,364,131

73,885,548

120,722,622

71,578,975


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting